Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Individualized Treatment
100%
Phase II Trial
100%
Radiation Therapy
100%
Head-and-neck Cancer
100%
Cetuximab
100%
Cancer Outcomes
100%
Radiotherapy
85%
Cisplatin
57%
Biological Markers
42%
Zirconium-89 (89Zr)
42%
Predictive Value
28%
Patient Selection
28%
Locoregional Control
28%
Adaptive Radiotherapy
28%
Simultaneous Integrated Boost
28%
Tumor
14%
Quality of Life
14%
Multicenter Trial
14%
Radiation Dose
14%
Treatment Outcome
14%
Adaptation
14%
Chemoradiation
14%
Overall Survival
14%
Improved Outcomes
14%
Randomized Phase II Trial
14%
Irradiation
14%
2-design
14%
Locally Advanced
14%
Tumor Response
14%
Epidermal Growth Factor Receptor
14%
Progression-free Survival
14%
Gross Tumor Volume
14%
Head-and-neck
14%
Swallowing Function
14%
Oral Cavity
14%
Anatomical Changes
14%
Loading Dose
14%
Effective Dose
14%
Dose Distribution
14%
Clinical Target Volume
14%
Local Recurrence-free Survival
14%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
14%
Enhancing Tumor
14%
Function Preservation
14%
Hypopharynx
14%
Volume-targeted
14%
Patient's Will
14%
Oropharynx Squamous Cell Carcinoma
14%
Medicine and Dentistry
Phase II Trials
100%
Cancer Therapy
100%
Cetuximab
100%
Head and Neck Cancer
100%
Radiation Therapy
100%
Cisplatin
57%
Neoplasm
42%
Biological Marker
42%
Patient Selection
28%
Adaptive Radiotherapy
28%
Quality of Life
14%
Overall Survival
14%
Recurrent Disease
14%
Swallowing Function
14%
Neck
14%
Progression Free Survival
14%
Chemoradiotherapy
14%
Squamous Cell Carcinoma
14%
Hypopharynx
14%
Oropharynx
14%
Oral Cavity
14%
Loading Drug Dose
14%
Local Recurrence Free Survival
14%
Biopsy Technique
14%
Epidermal Growth Factor Receptor Antibody
14%
Polyethylene Terephthalate
14%
INIS
cancer
100%
radiations
100%
radiotherapy
100%
patients
75%
doses
37%
tumors
37%
biological markers
37%
uptake
37%
values
25%
volume
25%
control
25%
toxicity
25%
antibodies
12%
increasing
12%
biopsy
12%
tissues
12%
correlations
12%
receptors
12%
quality of life
12%
design
12%
radiation doses
12%
failures
12%
positron computed tomography
12%
carcinomas
12%
loading
12%
irradiation
12%
growth factors
12%
preservation
12%
oral cavity
12%
effective doses
12%
dose distributions
12%
Pharmacology, Toxicology and Pharmaceutical Science
Phase II Trials
100%
Malignant Neoplasm
100%
Cetuximab
100%
Head and Neck Cancer
100%
Cisplatin
57%
Neoplasm
42%
Biological Marker
42%
Overall Survival
14%
Squamous Cell Carcinoma
14%
Recurrent Disease
14%
Progression Free Survival
14%
Chemoradiation Therapy
14%
Local Recurrence Free Survival
14%
Epidermal Growth Factor Receptor Antibody
14%
Polyethylene Terephthalate
14%